Longeveron Reports Significant MACE Result in ELPIS II HLHS Trial

What happened

Longeveron said laromestrocel had fewer major adverse cardiac events than standard care in its ELPIS II trial, 8 versus 1 with a P value of 0.043. The trial missed its primary endpoint: change in right ventricular ejection fraction at Month 12.

Confirmed

Global impact / market context

Fewer major heart events suggest a possible safety or clinical benefit even though the main heart-function measure was not met. Longeveron plans to ask the FDA to review the results, and that meeting could shape whether the HLHS program continues.

Analyst inference

The mixed result leaves investors weighing a missed primary endpoint against statistically significant secondary event data. For a small company, an FDA meeting decision may matter more than the trial data alone because it can change plans and funding needs.

Analyst inference

What to watch

1. Longeveron intends to request an FDA meeting to review the ELPIS II results and discuss potential next steps for its HLHS program. Confirmed
2. Watch whether the FDA agrees to meet, and what design or endpoint changes the company proposes for any future HLHS trial. Proposed
3. Track Longeveron's spending and cash needs, since another trial would likely raise costs before any revenue is possible. Analyst inference

Evidence

• Original source link unavailable